// App-Quantinova.ai

313 : Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Laurence Albiges

  • Elizabeth R. Plimack

  • Saby George

  • Thomas Powles

  • Frede Donskov

  • Brian I. Rini

  • Viktor Grnwald

  • Hans J. Hammers

  • Toni K. Choueiri

  • Howard Gurney

  • Scott S. Tykodi

  • Camillo Porta

  • Mauricio Burotto

  • Yoshihiko Tomita

  • Chung-Wei Lee

  • Chad Tang

  • David F. McDermott

  • Rana R. McKay

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Fox Chase Cancer Center, Philadelphia, PA

  • Roswell Park Cancer Institute, Buffalo, NY

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Aarhus University Hospital, Aarhus, Denmark

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • University Hospital of Essen, Essen, Germany

  • UT Southwestern Kidney Cancer Program, Dallas, TX

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Westmead Hospital and Macquarie University, Sydney, Australia

  • University of Washington, Seattle, WA

  • University of Bari Aldo Moro, Bari, Italy

  • Bradford Hill Research Center, Santiago, Chile

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Bristol-Myers Sqiubb, Princeton, NJ

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Beth Israel Deaconess Medical Center/ Dana-Farber Cancer Institute, Boston, MA

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

Locations

  • United States

  • France

  • United Kingdom

  • Denmark

  • Germany

  • Australia

  • Italy

  • Chile

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02231749

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved